The Valley Desk

ArticleTherapeutic innovation & regulatory sciencePublished

Evaluating Post-Progression Survival in the Context of Progression-Free Survival Benefits: A Revisit of the CodeBreaK200 Design

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source

Publication record

Type
Article
Venue
Therapeutic innovation & regulatory science
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Pyrimidines; Antineoplastic Agents; Randomized Controlled Trials as Topic; Docetaxel; Progression-Free Survival; Overall Survival; Progression-free Survival; Informative Censoring; Crossover
PubMed ID
41665865
Added to directory
Source checked

Report a correction or request removal